ABSTRACT
The 35th annual congress of the European Association of Nuclear Medicine (EANM) brought together specialists and professionals from molecular imaging and radionuclide ther-apy disciplines from across Europe and the rest of the world. After 2 years of virtual editions due to the COVID-19 pandemic restrictions, this year the meeting was held in person, in Bar-celona, with nearly 7,000 attendees and over 150 sessions. This report summarizes some of the research highlights on radiopharmaceutical product candidates presented at the meeting.
ABSTRACT
Targeted alpha therapy offers unique opportunities for the treatment of tumours and infections. Here, we report the development of a new radioimmunoconjugate construct that targets SARS-CoV-2 infected cells, which act as viral reservoirs and promote virus replication and infection spread. The chosen antibody selectively binds to the ACE2-receptor binding domain of the spike protein, and prevents the protein binding to the receptor. Furthermore, the antibody has been radiolabelled with 225Ac, and the therapeutic performance of the resulting radioimmunoconjugate has been demonstrated in vitro against cells mimicking SARS-CoV-2 infection.